We prospectively monitored 74 consecutive allogeneic and 50 autologous patients after bone marrow/stem cell transplantation from May 1999 to October 2000 at our institution with quantitative CMV PCR and pp65 antigen assay once weekly from conditioning therapy to days 120 and 80 after transplantation, respectively. Written informed consent was obtained from every patient. CMV prophylaxis consisted of acyclovir during transplant. Additionally all patients received only platelet products from CMV-negative donors. In the case of CMV infection preemptive therapy with gancyclovir was applied. In the case of CMV disease high-dose immunoglobulin was given as well. In the allogeneic setting 16 out of 74 (22%) patients developed a positive PCR. Seven episodes of a positive pp65 antigen assay occurred in six allograft recipients. In the autologous setting no positive assay was found during the whole observation period. Additionally, in 6/16 patients a lymphoproliferative assay was performed during CMV infection. Two patients showed a positive (15 and 5.4) and four a negative (2,1.6,1,1.8) stimulation index. Bone Marrow Transplantation (2001) 28, 765-768. Keywords: CMV; pp65; quantitative PCR; transplantation Despite preventive and therapeutic antiviral medication cytomegalovirus (CMV) infection is still a major cause of morbidity and mortality after bone marrow (BM) or peripheral blood stem cell (PBSC) transplantation.
Despite preventive and therapeutic antiviral medication cytomegalovirus (CMV) infection is still a major cause of morbidity and mortality after bone marrow (BM) or peripheral blood stem cell (PBSC) transplantation.
1,2 Especially CMV-seropositive patients are at high risk for developing CMV infection. 2 The incidence of CMV infection is higher following allogeneic than autologous transplantation. 3 CMV disease occurs in the period 28 to 72 days after transplantation. It can affect several organs, primarily the lungs (interstitial pneumonitis) and the gut. Despite some improvements (new antiviral agents, combination therapy) the fatality rate for CMV pneumonia is still high. Considering CMV infection as the most significant risk factor for the occurrence of CMV disease early detection is warranted in order to prevent the progression to disease. Until recently the standard diagnostic method to detect CMV infection in transplant patients has been the pp65 antigen assay, which detects a CMV-specific antigen expressed by cells early after infections. 4 Then the polymerase chain (PCR) reaction was established by Einsele et al. 5 Shortly afterwards followed the application of a quantitative PCR on bone marrow transplantation patients as described by Gerna et al. 6 The value of monitoring patients after allogeneic stem cell transplantation (SCT) by quantitative PCR has not been evaluated. Therefore, we report our experience with this new method in comparison with the pp65 antigen assay.
Patients and methods

CMV quantitative PCR assay
Quantitative CMV PCR was performed in parallel on plasma and whole blood samples prepared from the same EDTA tube according to the instructions of the manufacturer using the semiautomated Cobas Amplicor CMV Monitor test (Roche Diagnostic Systems, Branchburg, NJ, USA). 6 Results were recorded as number of viral copies per milliliter of plasma or EDTA blood with a cut-off level of 400 copies per milliliter (copies/ml) according to the manufacturer's recommendations (Roche Diagnostic Systems) and described recently.
CMV pp65 antigenemia assay
The CMV pp65 antigenemia assay was performed on peripheral blood leukocytes (PBLs) applied to slides by cytocentrifugation of 200 000 cells each as described elsewhere 7 using first Clonab CMV monoclonal antibody (Biotest, Dreieich, Germany) and conjugated rabbit antimouse Ig (Dako, Glostrup, Denmark) as second antibody for color development. A positive assay requires the presence of at least one positive cell per slide.
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Lymphoproliferative assay
The assay was performed as described elsewhere. 8 In brief, peripheral blood mononuclear cells were suspended at 10 6 cells/ml dispensed in triplicate into 96-well round-bottom plates. CMV antigen or PHA was added at final concentrations of 1:100 and 10 mg/ml, respectively. The plates were then incubated at 37°C in a humidified 5% CO 2 atmosphere for 96 h. During the last 16 h of the incubation period, the cells were pulsed with 1 Ci per well of 3 Hthymidine. Wells were harvested and samples were measured in a ␤-scintillation counter. Results are expressed as a stimulation index calculated by dividing the mean counts per minute (c.p.m.) of cells exposed to the CMV antigen and PHA by the mean c.p.m. of cells incubated with medium alone. A stimulation index of 3 or greater was considered to indicate a positive lymphoproliferative response. This definition was based on results obtained from five CMV seronegative healthy blood donors.
Definitions
CMV infection was defined as a positive antigenemia assay and/or two consecutive positive PCR assays within 1 week. CMV disease was defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture in bronchoalveolar fluid in the presence of new or changing pulmonary infiltrates.
Patients
Patient characteristics are presented in Table 1 . The graftversus-host disease prophylaxis in the allogeneic patients was administered according to the Seattle protocol. 9 Pretransplant CMV serology in the allogeneic setting showed that in 76% either recipient and/or donor were positive. Patients with the constellation of donor and/or recipient CMV seropositivity pretransplant are referred to as high risk patients for CMV infection as described in the literature. 10, 11 Thirty (60%) of 50 autologous patients were CMV seropositive pretransplant.
CMV prophylaxis
In the allogeneic setting CMV prophylaxis consisted of acyclovir 3 × 500 mg/m 2 /day from the beginning of conditioning until day +30. In the autologous setting acyclovir (2 × 250 mg/m 2 /day) was given from start of the conditioning therapy until dismissal. Additionally, all patients received only platelet products from CMV negative donors.
Preemptive therapy
After day +30, all patients were screened for CMV pp65 antigen and PCR weekly. In the case of positive antigen detection and/or positive PCR for two consecutive tests within 1 week preemptive therapy with gancyclovir 2 × 5 mg/kg body weight/day for 14 days was applied. In the case of CMV disease high-dose immunoglobulin was applied according to the Seattle regimen 4 in addition. 3 -AML = acute myeloid leukemia; CML = chronic myeloid leukemia; NHL = non-Hodgkin's lymphoma; MM = multiple myeloma; SAA = severe aplastic anemia; SLE = systemic lupus erythematodes; Cy = cyclophosphamide; Mel = melphalan; ATG = antithymocyte globulin; TBI = total body irradiation, PBSC = peripheral blood stem cells; BM = bone marrow.
Results
CMV infection and disease
Sixteen of 124 (13%) patients developed a positive PCR after a median time of 47 days (range, 29-78) post transplant as shown in Table 1 . All 16 patients had received an allogeneic SCT. A Kaplan-Meier curve for time to PCR positivity is shown as Figure 1 . Sixteen (29%) of the 56 high risk patients developed CMV infection vs none of the 68 standard risk patients. Seven episodes of a positive pp65 antigen assay occurred in six allograft recipients. In seven episodes both pp65 antigen and PCR were positive (Figure 2 ), in 10 episodes a positive PCR together with a negative antigen assay were found, and there was no episode with a positive antigen assay and a negative PCR (Table 1 ). In cases of positive pp65 antigenemia assay this was preceded by a positive PCR a median of 11 days and the PCR remained positive for a median of 16 days after clearance of CMV antigenemia. Three allogeneic patients developed CMV enteritis. All three patients showed positive antigen assay and PCR (in two cases at the time of diagnosis, in one case about 1 month before diagnosis of CMV disease). In two cases the patients developed clinical symptoms simultaneously with the detection of CMV infection by PCR. In one case the patient became symptomatic after about 1 month of antiviral treatment. The clinical diagnosis was confirmed by endoscopically obtained biopsies in all cases. The interval between beginning of treatment and onset of CMV disease were 2, 5 and 28 days, respectively. One of them recovered fully after 59 days of therapy, the other two patients eventually died due to organ toxicity after 69 and 49 days of antiviral therapy, respectively. Figure 3 shows the response of patients to antiviral therapy measured by quantitative PCR. The median value at start of therapy was 37 562 copies/ml (range, 800-78 000). After 1 week the PCR decreased to normal levels in four episodes. After the second week PCR was normal in another four episodes. Thereby altogether eight of 13 episodes showed clearance of PCR copies within 2 weeks of antiviral therapy. Out of the five non-responders, three developed CMV disease. The median duration of antiviral therapy was 25 days (range, 14-69 days).
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Days of treatment 
CMV infection and GVHD
In eight of 16 (50%) patients active GVHD occurred together with CMV infection and/or disease. All five patients who showed elevated copy numbers after 14 days of antiviral treatment at the same time suffered from acute GVHD.
Lymphoproliferative response
In 6/16 patients the lymphoproliferative assay was performed during CMV infection as described above. Two patients showed a positive (15 and 5.4) and four a negative (2, 1.6, 1, 1.8) stimulation index. In patients with a negative stimulation index the median virus load was 106 333 c/ml (range, 7000-227 000) and the copy numbers remained high after 2 weeks of treatment. The two patients with a positive stimulation index had a virus load of 800 and 78 000 c/ml and both patients cleared PCR copies after 2 weeks of treatment.
Transplant-related mortality and overall survival
Of the 74 allogeneic patients, 16 (22%) died of transplantrelated causes after a median of 119 days (range, 10-450) post transplant; two of the 16 deaths were CMV related, seven were related to multiorgan failure, four to bacterial infection, two to cerebral hemorrhage, and one to intestinal GVHD, respectively. In the autologous setting, the TRM was 2% (1/50), without evidence of CMV infection. The overall survival after a median observation time of 9.3 (range, 1-17) and 11.2 (range, 1-17) months for allogeneic and autologous patients was 73% and 88%, respectively.
Discussion
In the 124 consecutive patients we observed 17 episodes of positive CMV PCR. It is noteworthy that despite a high number of unrelated transplants (48% of allogeneic transplants) we found a lower incidence of CMV infection and disease in our patient population compared to recently published data. 12 Additionally, no autologous patient experienced CMV infection. This compares favorably with recent reports. 13 These findings may be the result of preemptive therapy and the strict use of blood products from CMV-seronegative donors only in all our patients. Additionally, we did not apply T cell-depleted grafts. Furthermore, we found a better correlation of the quantitative PCR than the antigen assay with the course of CMV infection as indicated by the earlier increase and clearance of copies as described in the Results.
The reason for the different treatment response in our patient population as depicted in Figure 2 is unknown. Due to the lack of data about drug resistance of different CMV strains resistance cannot be discussed here as a parameter influencing therapy. One can speculate that conditions impairing cellular immunity like GVHD 14 or relapse of the underlying disease negatively influence treatment response since cellular immunity has been found to be necessary to overcome CMV infection. 8, 15 Our results of the lymphoproliferative assays seem to underline the importance of cellular immunity. In our series, patients with a positive lymphoproliferative response against CMV seemed to harbor a lower virus load and a more rapid clearance of CMV compared to their negative counterparts. Although the number of patients in our study is small our data further stress the importance of CMV immunity in clearing CMV infection in the allogeneic setting. Moreover, our results suggest that GVHD and the corresponding medication are depriving the patient of cellular immune protection against viral infections since they increased the susceptibility of the patient for CMV infection and impaired the response to antiviral treatment in our patient population.
In conclusion, we found an earlier positivity of the CMV PCR compared to pp65 antigen assay. By using preemptive therapy we observed a lower incidence of CMV infection and disease compared to previous reports. Thus, we recommend the beginning of antiviral therapy after two consecutive positive CMV PCRs. Furthermore, we have to emphasize the importance of the exclusive use of blood products from CMV-seronegative donors. Additionally, we found a negative impact of GVHD on the course of CMV infection. Further studies should evaluate the role of a maintenance therapy for patients at high risk for CMV reactivation.
